摘要:
The present invention relates to the treatment of an arthritic disease such as rheumatoid arthritis with a kynurenine aminotransferase, a living recombinant bacterium which has been genetically modified to express and secrete said kynurenine aminotransferase, and/or a product of said kynurenine aminotransferase which is xanthurenic acid, a derivative thereof, or any pharmaceutically acceptable salt or solvate thereof.
摘要:
The present invention relates to the treatment of inflammatory bowel diseases with a kynurenine aminotransferase, a living recombinant bacterium which has been genetically modified to express and secrete said kynurenine aminotransferase, and/or a product of said kynurenine aminotransferase which is xanthurenic acid, a derivative thereof, or any pharmaceutically acceptable salt or solvate thereof.
摘要:
The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.
摘要:
The present invention relates to the preventive or curative treatment of metabolic syndrome and associated disorders, and inflammatory bowel diseases using Coprococcus bacteria and/or culture supernatants thereof.
摘要:
The invention relates to a bacterial strain of species Faecalibacterium prausnitzii deposited at the CNCM under access number CNCM I-4573, for use in the treatment and/or prevention of an inflammatory gastrointestinal illness in an individual.